Trial Profile
A Phase 1a/1b Study of COM701 as Monotherapy and In Combination With an Anti-PD-1 Antibody in Subjects With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs COM 701 (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Carcinoma; Colorectal cancer; Endometrial cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Compugen
- 10 Feb 2024 Planned End Date changed from 1 Dec 2023 to 31 May 2024.
- 10 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 29 Feb 2024.
- 06 Mar 2023 According to a Compugen media release, data was presented at the annual meeting of the Society for Immunotherapy of Cancer, 2022.